Genmab — Januar 2019
-
2,5 mia kr i overskud og 5 mia på bogen. 61 mio aktier findes der. Giver 41kr pr aktie. Vækst aktie/biotek, p/e bør vel være 40.= 1700kr pr altie.
-
Bliver spændende at følge luk i dag
-
Håber da på 600 mio$ Dara i q4 2018. Stiger ca 75 pr kvartal og forhåbentlig mere efter 1. Linje. Minimum 3 mia i
år. Det får Genmab ca 600 mio $ (17% plus diverse milestone) for = 4 mia kr. Udgifter til udvikling af pipeline 1,5 mia kr. 2,5 mia kr i overskud -
Regeneron's CD20xCD3 bispecific antibody, REGN1979, continues to progress with a potentially pivotal Phase 2 study in Follicular Lymphoma anticipated to begin in the first half of 2019 and a potentially pivotal Phase 2 study in Diffuse Large B-Cell Lymphoma anticipated to begin in the second half of 2019.
-
-
Bluebird køber sig til lidt car-t og stiger på det https://seekingalpha.com/news/3421135-bluebird-bio-8-percent-car-t-development-deal-inhibrx?app=1
- ( kun en oplysning )
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind